Joe Rogan Experience #2319 - Rick Doblin

The Joe Rogan Experience
02:14:12 Report Issue
Loading transcript... Click for full transcript

Chapters & Sections (288)

00:01 Podcast Introduction and Unexpected Guest Arrival chapter 1
00:01 Host Introduction and Guest Invitation
00:33 Ukraine Field Work and Trauma Context chapter 1
00:33 Travel to Ukraine and Training Overview
01:05 Legal Landscape for Psychedelic Research in Ukraine chapter 5
01:05 Legal Restrictions on Psychedelic Research in Ukraine
01:35 Draft Legislation and Government Efforts
02:06 Field Experience in Lviv and Air Raid Sirens
02:36 Cemetery Visit and Emotional Impact
03:09 Discussion of Trauma in Conservative Societies
03:41 Personal Mission and Future Plans chapter 2
03:41 Personal Representation and Philanthropic Goals
04:12 Upcoming Speaking Engagements in Beirut
04:43 Frustrations with Legal Progress and Historical Context chapter 1
04:43 Frustration with Legal Progress and Anecdotal Evidence
05:17 Early History of MDMA in Therapy and Culture chapter 2
05:17 Early Use of MDMA in Therapy Circles
05:48 Transition to Party Drug and the Stark Club Story
06:21 Personal Anecdotes Involving Larry Hagman and Psychedelic Culture chapter 2
06:21 Larry Hagman’s Connection to Psychedelic Culture
07:23 Personal Interaction with Larry Hagman and Genie Bong Anecdote
08:24 Early Psychedelic Experiences and Public Perception chapter 2
08:24 Psychedelic Culture in the 1960s
08:55 Positive Drug Story from a Beloved Star
09:26 Founding MAPS Amidst the Drug War chapter 2
09:26 MAPS Origins During the Reagan Era
09:56 Frustration and Persistence in Early MAPS Work
10:29 Legal Battles Over MDMA Scheduling chapter 3
10:29 Administrative Law Judge Decision on Scheduling
11:02 Appeals Court Challenges to DEA Decisions
11:32 DEA Reassessment and Legal Strategy
12:03 DEA Authority and FDA Pathway for Psychedelic Medicine chapter 3
12:03 Public Domain Status of MDMA and MAPS Mission
12:33 Illegal Emergency Scheduling by the DEA
13:05 Future of Psychedelic Research and Conferences
13:37 Impact of Criminalization on Public Health chapter 5
13:37 Frustration Over Prohibitionist Laws
14:09 Comparing Prescription Drug Availability to Psychedelics
14:40 Historical Misconceptions About Crack Babies
15:12 Stigma and Criminalization of Pregnant Drug Users
15:45 Counterproductive Effects of the Drug War on Public Health
16:14 Challenges of Decriminalization and Safe Injection Sites chapter 2
16:14 Needle Park and Safe Injection Site Experience
16:46 Overwhelming Capacity and Open‑Air Drug Market
17:17 Local Solutions vs. Citywide Impact in Portland chapter 2
17:17 Portland’s Transformation from Hippie Hub to Overcrowded City
17:47 Local Solutions Attracting Wider Populations
18:49 Humanizing Substance Abuse and Public Perception chapter 1
18:49 Humanizing Approach to Substance Abuse
19:21 Political Support for Psychedelic Therapy chapter 2
19:21 Rick Perry’s Support for Psychedelic Initiatives
20:11 Political Divide on Psychedelics
20:54 Therapeutic Context and Integration of Psychedelics chapter 1
20:54 Therapeutic Clinics vs. Ketamine Without Therapy
21:25 Neuroplasticity and Long‑Term Change from Psychedelic Experiences chapter 2
21:25 Importance of Integration and Preparation in Psychedelic Treatment
22:27 Neuroplasticity and Critical Periods from Psychedelics
24:01 Neurorehabilitation and Psychedelic Research Overview chapter 2
24:01 Researcher Collaboration with Military Veterans
24:32 Potential for Non-Psychedelic Psychedelics in Neurological Disorders
25:04 Psychological Concerns and Non-Psychedelic Alternatives chapter 2
25:04 Public Perception and Safety Concerns
25:35 Cluster Headache Intervention with Psychedelic Substances
26:06 Cluster Headache Case Study and Institutional Challenges chapter 2
26:06 Institutional Resistance and Ethical Hurdles
26:37 Strategic Use of Non-Cychedelic LSD Derivatives
27:09 Non-Cychedelic LSD Derivatives in Clinical Trials chapter 3
27:09 Clinical Trial Design and Outcome Expectations
27:39 Results of Bromodex Study and Comparative Efficacy
28:11 Funding Challenges for Non-Psychedelic Therapies
28:42 Funding, Advocacy, and Political Engagement chapter 2
28:42 Political Advocacy and Military Support
29:14 Bridging Perspectives Between Advocates and Skeptics
30:17 Personal Philosophy on Discipline and Consciousness Expansion chapter 2
30:17 Personal Reflection on Discipline Versus Consciousness Expansion
30:48 Concluding Thoughts on Work Ethic and Psychedelic Use
31:50 Historical Attitudes Toward Marijuana and Scientific Advocacy chapter 3
31:50 Carl Sean as a Hidden Stoner Scientist
32:22 Mentorship and Medical Research on Marijuana
32:54 Personal Reflections on Drug Law Reform
33:25 Legal Challenges and State-Level Reform Efforts chapter 4
33:25 Texas Attorney General and Austin Decriminalization Conflict
33:56 Game Warden Investigation of Illegal Grow Operations
34:27 Cartel-Controlled Marijuana Production in National Forests
34:58 Illicit Market Economics and Illegal Pesticide Use
35:31 Criminalization, Organized Crime, and the Economics of Illicit Markets chapter 1
35:31 Legalization vs. Criminalization Debate on Tax Revenue
36:01 Comparative Substance Regulation and Historical Prohibition Lessons chapter 4
36:01 Attorney General’s Argument for Decriminalization
36:33 Comparing Alcohol and Marijuana Regulation
37:04 Historical Impact of Prohibition on Organized Crime
37:35 Social Acceptance and Personal Choice Regarding Substances
38:05 Therapeutic Potential of Psychedelics in End-of-Life Care chapter 2
38:05 Psychedelics for End-of-Life Anxiety
38:38 Public Figures and Psychedelic Advocacy
39:08 Legalization, Taxes, and Youth Education chapter 2
39:08 Taxation of Marijuana in Different States
39:40 Economic Benefits vs. Youth Risks
40:11 Cultural Contexts of Psychedelic Use chapter 2
40:11 Peyote Ceremonies in Indigenous Communities
40:42 Age and Dosage Considerations in Ritual Use
41:13 Ceremonial Use and Developmental Impact chapter 2
41:13 Ceremonial Settings Reduce Developmental Harm
41:43 Rituals and the Formation of Adult Identity
42:14 Personal Growth Through Rituals chapter 1
42:14 Bar Mitzvah as a Failed Rite of Passage
43:47 Psychedelics as Modern Rite of Passage chapter 2
43:47 LSD Experience as Personal Rite of Passage
44:20 Comparing European and American Youth Substance Use
45:19 Comparative Substance Use and Regulation chapter 1
45:19 Prohibition Effects on Drug Potency
46:56 Risks of Ecstasy and Exercise chapter 3
46:56 Hyperthermia and Overhydration from MDMA Use
47:28 Rhabdomyolysis from Excessive Exercise
48:29 Statistical Comparison of Rabdo and Water Overconsumption
49:00 Comparing Dangerous Activities chapter 2
49:00 Horseback Riding vs. Ecstasy in Risk Rankings
49:31 Cheerleading and Other Physical Activities as High-Risk Sports
50:33 Propaganda, Policy and Public Perception chapter 2
50:33 Legalization of Dangerous Recreational Activities
51:36 Propaganda and the Misrepresentation of Drug Risks
52:06 Psychedelics as Therapeutic Tools for Trauma chapter 3
52:06 Need for Evidence-Based Policy on Psychedelics
53:08 Psychedelic Therapy for PTSD and Sexual Abuse Survivors
54:12 Veterans Administration Collaboration with MAPS
54:45 Funding and Research Initiatives for MDMA Therapy chapter 2
54:45 VA Stigma and Initial Funding for MDMA Studies
55:16 $10 Million Defense Grant for MDMA Research
55:46 Comparative Effectiveness of Traditional PTSD Therapies chapter 2
55:46 Veterans Administration PTSD Study Overview
56:18 Retraumatization in Traditional Exposure Therapies
56:49 Combining MDMA with Various Psychotherapeutic Approaches chapter 3
56:49 MDMA with Prolonged Exposure Trial in Texas
57:20 MDMA Combined with Acceptance and Commitment Therapy at Walter Reed
57:53 Cognitive Behavioral Conjoint Therapy Development
58:25 Historical Context and FDA Oversight of MDMA Research chapter 2
58:25 Early FDA Approval and Historical Use of MDMA
58:58 Serotonin Depletion Concerns and 5HTP Discussion
59:29 Therapeutic Protocols and Post-MDMA Care chapter 5
59:29 Two-Day MDMA Therapy Protocol
1:00:33 Post-MDMA Rest and Integrative Sessions
1:01:04 Family-Centered MDMA Therapy for Cancer Patients
1:01:34 Expanding MDMA Therapy to Veterans and Partners
1:02:04 Challenges of Scaling PTSD Treatment in the U.S.
1:03:07 Group Therapy Initiatives for Military Trauma chapter 3
1:03:07 Early Group Therapy Pilot at Portland VA
1:03:40 Separating Military Sexual Trauma Groups
1:04:10 Adding a Third MDMA Session in Group Format
1:04:42 International and Climate-Related PTSD Studies chapter 2
1:04:42 Climate-Related PTSD Study in Australia
1:05:13 Israel Post‑October 7th Trauma Group Trial
1:05:43 Comparative Effectiveness of Individual vs. Group Therapy chapter 2
1:05:43 Individual vs. Group Therapy Randomized Comparison
1:06:47 Hybrid Individual/Group Integration Model at Sunstone
1:07:19 Regulatory and Timeline Considerations for MDMA-Assisted Group Therapy chapter 2
1:07:19 FDA Approval Timeline for Group Therapy
1:07:50 Challenges of Double‑Blind Psychedelic Trials
1:08:20 Designing Double-Blind Psychedelic Studies chapter 4
1:08:20 Low vs. Full Dose MDMA in Therapy
1:08:51 Dose‑Response Studies from Phase 2 Trials
1:09:21 Unexpected Findings in Low Dose MDMA Efficacy
1:10:57 Veteran, Firefighter, and Police Officer Dose Comparison
1:11:28 Randomization and Initial Findings chapter 2
1:11:28 Evaluating Depression and PTSD Symptoms in Randomized Groups
1:12:01 Therapeutic Dose Determination and Unexpected Outcomes
1:12:33 FDA Phase 2 to Phase 3 Transition chapter 2
1:12:33 FDA Phase 2 Meeting and Transition to Phase Three
1:13:04 Special Protocol Assessment Negotiations with FDA
1:13:36 Designing a Double-Blind Study chapter 2
1:13:36 Random Assignment and Independent Rating Procedures
1:14:06 Telemedicine Assessment Using CAPS Scale
1:15:07 Challenges with FDA Advisory Committee chapter 2
1:15:07 FDA Advisory Committee Concerns About Functional Unblinding
1:15:40 Discussion of Double-Blind Limitations in Psychedelic Studies
1:16:42 Negotiations and Potential Approval Pathways chapter 1
1:16:42 Negotiation Outcomes and Potential Phase 4 Pathway
1:17:45 Phase Three Study Outcomes – Severe PTSD chapter 2
1:17:45 Phase Three Study Results – Severe PTSD
1:18:05 Responder Rates and Clinical Significance in Severe PTSD Study
1:18:47 Phase Three Study Outcomes – Moderate to Severe PTSD chapter 2
1:18:47 Phase Three Study Results – Moderate to Severe PTSD
1:19:19 Control Group Outcomes and Therapist Effort in Moderate Study
1:19:50 Therapeutic Approach and MDMA Research chapter 3
1:19:50 Therapeutic Structure and Dropout Rates
1:20:22 Supportive Therapy Model for Psychedelic Sessions
1:21:23 Fidelity and Safety Outcomes in MDMA Trials
1:22:30 Personal Journey into Psychedelic Advocacy chapter 3
1:22:30 Advocacy and Legislative Efforts
1:23:33 Early Interest in Psychedelics and Vietnam Draft Resistance
1:24:37 Guidance Counselor Support and Influential Literature
1:26:41 Early Dreams and Influences chapter 1
1:26:41 Dream Narrative of Survival and Purpose
1:27:43 Psychedelic Vision and Interconnectedness chapter 3
1:27:43 Jesus Theme in Psychedelic Experience
1:28:13 Interconnectedness and Dehumanization Prevention
1:28:45 LSD Storage and Youth Connection
1:29:17 Personal Psychedelic Journey and Motivation chapter 3
1:29:17 Motivation from Psychedelic Experiences
1:29:50 Family Refugee Background and American Dream
1:30:20 Privileged Jewish Identity and Responsibility
1:31:23 Family Heritage and Privilege chapter 3
1:31:23 Privilege as a Catalyst for Social Change
1:32:27 Maslow and Economic Survival Constraints
1:32:58 Mission to Reintroduce Psychedelic Healing
1:34:01 Psychedelic Renaissance and Regulatory Landscape chapter 3
1:34:01 FDA Response and Research Momentum
1:34:33 Interconnectedness as a Barrier to War
1:35:06 Historical Psychedelic Influence on Culture
1:36:40 Political Use of Drug Criminalization chapter 1
1:36:40 Nixon Administration's Drug Strategy
1:37:13 Historical Psychedelic Practices and Suppression chapter 3
1:37:13 Elocidian Mysteries and Psychedelic Potions
1:37:43 Church Suppression of Psychedelics
1:38:15 Witch Hunts and Indigenous Shaman Suppression
1:38:46 Prehistoric and Medieval Plant Medicine Contexts chapter 1
1:38:46 Prehistoric Tribal Dynamics
1:39:16 Literary Reflection on Competition and Peace chapter 2
1:39:16 The Glass Bead Game and Post-War Idealism
1:39:48 Abstraction of the Glass Bead Game and Elite Control
1:40:18 Modern Psychedelic Advocacy and Global Conflict chapter 2
1:40:18 TED Talks on Psychedelics and Global Tension
1:41:20 Current Geopolitical Conflicts and Psychedelic Healing
1:41:50 Psychedelics as a Bridge in Israeli-Palestinian Relations chapter 4
1:41:50 Combatants for Peace Initiative
1:42:22 Visa Challenges for Palestinian Speakers
1:42:53 Neuroscience of Shared Psychedelic Experiences
1:43:25 Genetic and Tribal Roots of Conflict
1:43:59 Cultural and Genetic Roots of Conflict chapter 2
1:43:59 Fundamentalism vs. Mysticism in Religious Contexts
1:44:29 Human DNA Similarity and Interconnectedness
1:44:59 Interconnectedness and Appreciation of Diversity chapter 2
1:44:59 DNA and Human Commonalities
1:45:29 Suspension of Illusionary Mysteries and Power Dynamics
1:46:02 Control, Propaganda, and the Role of Context in Psychedelic Use chapter 3
1:46:02 Propaganda, Lies, and the Misuse of Psychedelic Tools
1:46:32 Religion, Power, and the Contextualization of Psychedelics
1:47:03 Therapeutic Integration and Cultural Context
1:47:35 Historical and Cultural Perspectives on Psychedelics chapter 4
1:47:35 Psychedelics in Historical Mythology (Vikings and Berserkers)
1:48:07 McKenna’s Stone Tape Theory Overview
1:48:38 Dennis’ Scientific Perspective on Psilocybin and Neuroplasticity
1:49:10 Evolutionary Hypothesis of Mushroom Use in Early Humans
1:49:42 Evolutionary Hypotheses and Modern Implications chapter 1
1:50:13 Psychedelics as a Catalyst for Human Evolution
1:51:18 Philosophical Reflections on Humanity’s Future chapter 2
1:51:18 Space Perspective and Interconnectedness
1:52:20 Evil, Conflict, and the Need for New Thinking
1:52:50 Reflections on Human Nature and the Shadow chapter 2
1:52:50 Danger of Human Self and the Need for Study
1:53:20 Shadow Psychology and Projection onto Others
1:53:50 Personal Psychedelic Experiences and Historical Reflections chapter 8
1:53:50 First DMT Experience with Terrence McKenna
1:54:23 Describing the Visual Journey of DMT
1:54:54 Realization of Universal Connection and Its Dark Implications
1:55:26 Linking Psychedelic Insight to Historical Trauma and MAPS Strategy
1:56:28 Ketamine Experience with Hitler Imagery and Grounding Techniques
1:57:30 Mass Mental Health Vision for MAPS
1:58:33 Drug Policy Reform and Education Initiatives
1:59:33 Historical Context of Nazi Drug Use and Its Consequences
2:00:35 Historical Context of Warfare and Psychedelic Use chapter 6
2:00:35 War Tactics and Alcohol Consumption
2:01:05 Discussion of Berserkers and Mushroom Use
2:01:39 Genetic and Soil Influences on Psychoactive Plants
2:02:10 Amanita Mascaria and Viking Hallucinogens
2:02:43 Modern Research on Amanita and Other Psychedelics
2:04:16 Henbane and Historical Witchcraft Connections
2:04:46 Exploration of Ancient Mushroom Lore chapter 2
2:04:46 Sacred Mushroom in Early Christianity
2:05:49 Genetic Studies of Amanita Persistence
2:06:19 Modern Scientific Insights into Psychedelics chapter 1
2:06:19 Urgot and Ancient Psychedelic Traces
2:06:51 Long-Term Cultural and Spiritual Development chapter 2
2:06:51 Suppression of Psychedelics in Ancient Societies
2:07:53 Multi-Generational Spiritual Projects
2:08:23 Conference Overview and Logistics chapter 5
2:08:23 Personal Reflections on Health and Hope
2:08:55 Conference Promotion and Speaker Lineup
2:09:26 Event Structure and Music Integration
2:09:58 Cross-Training for Psychedelic Therapists
2:10:29 Conference Dates, Venue, and Attendance Highlights
2:11:00 Global Outreach and Training Initiatives chapter 5
2:11:00 Engaging Federal Agencies and Police Training
2:11:31 Global Expansion into Low-Resource Trauma Settings
2:12:02 Future FDA Approvals and Global Access Plans
2:12:35 Immigration History and Cultural Integration
2:13:06 Border Security, Citizenship Pathways, and Community Support
2:13:37 Closing Remarks and Appreciation chapter 1
2:13:37 Final Thank Yous and Farewell

Transcript

Loading transcript...